Physician profile
Jennifer M Albert
NPI 1891221602
$380.07
in general payments reported to CMS, 2019-2025
10 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8.35 · 2022: $15.69 · 2023: $86.77 · 2024: $92.90 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $356.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $122.19 | 2025 | |
| Neurocrine Biosciences, INC. | $70.26 | 2023 | Ingrezza |
| Astrazeneca Pharmaceuticals Lp | $38.30 | 2024-2025 | Airsupra, Breztri |
| Corium, LLC | $33.86 | 2024 | Azstarys |
| Glaxosmithkline, LLC. | $32.07 | 2025 | Trelegy Ellipta |
| Pfizer INC. | $29.52 | 2022-2024 | |
| Lilly USA, LLC | $16.51 | 2023 | Mounjaro, Trulicity |
| Boston Scientific Corporation | $15.73 | 2024 | Watchman |
| Merck Sharp & Dohme LLC | $13.28 | 2024 | Gardasil 9, Vaxelis, Gardasil |
| Genentech USA, INC. | $8.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.